Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Neurochem: Can Europe be saved?

After three years and more than $50 million invested in a North American Phase III trial of Alzhemed tramiprosate for Alzheimer's disease, Neurochem Inc. has a trial that FDA says can't be used for efficacy claims. Nevertheless, the biotech thinks that the trial could hold nuggets that will help inform the design of other AD trials, including potential modifications to its ongoing European Phase III study of Alzhemed.

Last week, Neurochem (TSX:NRM; NRMX, Laval, Quebec) reported that Alzhemed, an inhibitor of

Read the full 816 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers